Aquinox Pharmaceuticals Inc (AQXP) : Boxer Capital scooped up 10,600 additional shares in Aquinox Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 820,015 shares of Aquinox Pharmaceuticals Inc which is valued at $7,634,340.Aquinox Pharmaceuticals Inc makes up approximately 8.10% of Boxer Capital’s portfolio.
Other Hedge Funds, Including , Susquehanna International Group Llp added AQXP to its portfolio by purchasing 23,839 company shares during the most recent quarter which is valued at $221,941.Proshare Advisors boosted its stake in AQXP in the latest quarter, The investment management firm added 168 additional shares and now holds a total of 12,814 shares of Aquinox Pharmaceuticals Inc which is valued at $119,298.Vanguard Group Inc boosted its stake in AQXP in the latest quarter, The investment management firm added 2,197 additional shares and now holds a total of 110,529 shares of Aquinox Pharmaceuticals Inc which is valued at $1,029,025.Tower Research Capital (trc) reduced its stake in AQXP by selling 2,451 shares or 99.84% in the most recent quarter. The Hedge Fund company now holds 4 shares of AQXP which is valued at $37.
Aquinox Pharmaceuticals Inc opened for trading at $10.57 and hit $13.75 on the upside on Thursday, eventually ending the session at $12.24, with a gain of 15.25% or 1.62 points. The heightened volatility saw the trading volume jump to 26,53,509 shares. Company has a market cap of $211 M.
Aquinox Pharmaceuticals Inc. formerly Aquinox Pharmaceuticals (USA) Inc. is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc. is a wholly owned subsidiary of the Company. The primary focus of the Company is anti-inflammatory product candidates targeting SHIP1 which is a regulator of a cellular signaling pathway in immune cells known as the PI3K pathway. Its lead product candidate AQX-1125 is a small molecule activator of SHIP1 suitable for oral once daily dosing. The Company has completed multiple preclinical studies and clinical trials with AQX-1125 it is advancing through Phase II development in several initial indications. The Company operates in Vancouver British Columbia Canada.